8-K: FibroGen to Sell China Operations to AstraZeneca for $160 Million, Extends Cash Runway into 2027

FibroGen is selling its China subsidiary to AstraZeneca for approximately $160 million, which includes $85 million for the enterprise value and an estimated $75 million in net cash held in China, extending the company's cash runway into 2027.

Summary

• FibroGen has entered into a share purchase agreement with AstraZeneca to sell its China subsidiary, FibroGen International, for approximately $160 million.
• The purchase price includes $85 million for the enterprise value and an estimated $75 million in net cash held in China.
• The transaction is expected to close by mid-2025, subject to customary closing conditions and regulatory approval from the China State Administration for Market Regulation.
• Upon closing, FibroGen intends to repay its term loan facility with Morgan Stanley Tactical Value, estimated to be around $80 million.
• AstraZeneca will acquire all rights to roxadustat in China, Hong Kong, and Macao.
• FibroGen will retain rights to roxadustat in the United States, Canada, Mexico, and markets not held by AstraZeneca or licensed to Astellas.
• FibroGen estimates it had approximately $121.1 million in cash, cash equivalents, and accounts receivable as of December 31, 2024.
• The company plans to continue advancing its oncology pipeline, including a Phase 2 trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) expected in the second quarter of 2025.
• Christine L. Chung, Senior Vice President, China Operations, will cease employment with FibroGen upon closing of the sale.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The sale provides financial stability and allows focus on core assets, but it also involves the departure of a key executive and reliance on estimates that could change.

Positives

• The sale of FibroGen China to AstraZeneca strengthens FibroGen's financial position.
• The transaction extends FibroGen's cash runway into 2027.
• Repaying the term loan to Morgan Stanley Tactical Value simplifies the company's capital structure.
• FibroGen can focus on advancing its oncology pipeline, particularly FG-3246.
• FibroGen retains rights to roxadustat in the U.S., Canada, Mexico, and other markets.
• The company is planning for an FDA meeting in the second quarter of 2025 to determine the potential next steps for the development program for roxadustat in the U.S.

Negatives

• Christine L. Chung, Senior Vice President, China Operations, will be leaving the company upon closing of the sale.
• The approximately $75 million of cash held in China is only an estimate and could change materially before closing.
• The total amount to be paid to Morgan Stanley Tactical Value is only our best estimate and includes principal, accrued and unpaid interest, and an applicable prepayment penalty, and could change materially before this term loan facility is paid off.

Risks

• The transaction is subject to customary closing conditions, including regulatory approval in China, which may not be obtained.
• The estimated net cash held in China is subject to adjustments and may change materially before closing.
• The repayment amount for the Morgan Stanley Tactical Value term loan is an estimate and could change materially.
• There is a $6.0 million hold back to offset final net cash adjustments which will be released following a customary adjustment process approximately 90 days post-closing.
• There is a $4.0 million hold back to satisfy any indemnity claims, which will be released, net of any claims paid or unresolved, nine months after the closing.

Future Outlook

FibroGen expects the sale to extend its cash runway into 2027 and enable continued progress in the clinical development program for FG-3246. The company also plans to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and is planning for an FDA meeting in the second quarter of 2025 to determine the potential next steps for the development program for roxadustat in the U.S.

Management Comments

• Thane Wettig, Chief Executive Officer of FibroGen, stated that the sale strengthens the company's financial position and enables continued progress in the clinical development program for FG-3246.
• Mr. Wettig also mentioned that selling the China operations and repaying the term loan is in the best interest of FibroGen's stakeholders.

Industry Context

This announcement reflects a strategic shift for FibroGen, focusing on its oncology pipeline while divesting its China operations to its long-time partner, AstraZeneca. This is not uncommon in the pharmaceutical industry, where companies often streamline operations to focus on core competencies and high-potential assets. AstraZeneca's acquisition of full rights to roxadustat in China aligns with its strategy to strengthen its presence in key markets.

Comparison to Industry Standards

• Divesting regional operations to partners is a common strategy in the pharmaceutical industry, similar to how companies like Novartis have partnered with local players in emerging markets.
• The valuation of $160 million for FibroGen's China operations is within the typical range for such transactions, although the specific multiple of revenue or earnings would depend on the profitability and growth prospects of the business.
• The focus on oncology drug development is a trend seen across the biopharmaceutical industry, with companies like Bristol Myers Squibb and Merck investing heavily in this area.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to extended cash runway and focus on core assets.
• Employees: Potential impact on China-based employees due to the sale; Christine Chung's departure.
• Customers: AstraZeneca will continue to provide roxadustat in China.
• Creditors: Morgan Stanley Tactical Value will be repaid.
• Suppliers: Potential changes in supply relationships as AstraZeneca takes over operations in China.

Next Steps

• Closing of the transaction by mid-2025, pending regulatory approval.
• Repayment of the term loan facility to Morgan Stanley Tactical Value.
• Initiation of the Phase 2 monotherapy trial of FG-3246 in mCRPC in the second quarter of 2025.
• FDA meeting in the second quarter of 2025 to determine the potential next steps for the development program for roxadustat in the U.S.

Key Dates

Keywords

FibroGen, AstraZeneca, Roxadustat, China, Sale, FG-3246, Oncology, Cash Runway, Term Loan, Anemia